Aug 26, 2026 07:00AM
Aug 26, 2026 07:00AM
Aug 3, 2026 07:00AM
May 18, 2026 07:00AM
Mar 2, 2026 07:00AM
Feb 12, 2026 07:00AM
Feb 12, 2026 07:00AM Compugen Announces the Appointment of Michele Holcomb, Ph.D., to its Board of Directors
Dec 17, 2025 07:02AM
Dec 17, 2025 07:00AM
Nov 10, 2025 07:00AM
Oct 17, 2025 10:00AM
Oct 17, 2025 10:00AM
Oct 13, 2025 07:00AM
Oct 13, 2025 07:00AM Compugen to Present Pooled Analysis of COM701 in Three Phase 1 Trials in Patients with Platinum Resistant Ovarian Cancer at ESMO 2025
Aug 6, 2025 07:00AM
Jul 21, 2025 07:00AM
Jun 9, 2025 08:00AM
Jun 1, 2025 09:00AM
May 19, 2025 07:00AM
May 13, 2025 07:04AM
May 13, 2025 07:00AM Compugen Announces Leadership Transitions Effective September 2025
Mar 4, 2025 07:00AM
Feb 26, 2025 07:00AM
Jan 30, 2025 11:00PM
Jan 8, 2025 07:00AM
Nov 27, 2024 07:03AM
Nov 27, 2024 07:00AM
Nov 12, 2024 07:00AM Compugen Reports Third Quarter 2024 Results
Nov 11, 2024 07:00AM
Nov 5, 2024 09:00AM
Oct 29, 2024 07:00AM
Oct 7, 2024 07:00AM
Sep 9, 2024 07:00AM
Aug 29, 2024 07:00AM
Aug 6, 2024 07:00AM Compugen Reports Second Quarter 2024 Results
Jul 29, 2024 07:00AM
Mar 5, 2024 07:00AM
Dec 19, 2023 07:01AM
Dec 19, 2023 07:00AM
Nov 6, 2023 07:05AM
Nov 6, 2023 07:00AM
Feb 27, 2023 07:00AM Compugen Reports Fourth Quarter and Full Year 2022 Results
Feb 14, 2023 07:00AM
Dec 6, 2022 07:00AM
Dec 1, 2022 07:09AM
Dec 1, 2022 07:00AM
Nov 7, 2022 08:05AM
Nov 7, 2022 08:04AM
Nov 7, 2022 08:00AM Compugen's COM701 (anti-PVRIG) Induces Potent Immune Activation in MSS-CRC Patients
Nov 7, 2022 08:00AM

330,185 total articles have been posted to this entity.

Click Here to Sign-Up for StreetInsider.com Premium to View All